Post by forthefuture on May 5, 2015 4:53:08 GMT
uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Just signed a deal with BMY in early April, with BMY buying shares at $33.84. Closed an offering in mid-April for almost $90M @ $29.50. So, they're well funded.
They have the first gene therapy approved in the western world for an ultraorphan disorder, and have several other therapies in the clinic or announced preclinical (such as the heart failure therapy they partnered with BMY). Stock is currently at $24 due to weakness surrounding questioning of their Glybera approval. Worst case scenario, the EMA makes them conduct another small study and revokes their approval until then. Potential continued weakness until there's some clarity around that, which should be in the next couple of weeks. Even if they were to revoke Glybera approval, shares should be valued higher than they currently are on a fundamental basis. I like this one long term.
www.uniqure.com/
Just signed a deal with BMY in early April, with BMY buying shares at $33.84. Closed an offering in mid-April for almost $90M @ $29.50. So, they're well funded.
They have the first gene therapy approved in the western world for an ultraorphan disorder, and have several other therapies in the clinic or announced preclinical (such as the heart failure therapy they partnered with BMY). Stock is currently at $24 due to weakness surrounding questioning of their Glybera approval. Worst case scenario, the EMA makes them conduct another small study and revokes their approval until then. Potential continued weakness until there's some clarity around that, which should be in the next couple of weeks. Even if they were to revoke Glybera approval, shares should be valued higher than they currently are on a fundamental basis. I like this one long term.
www.uniqure.com/